A tyrosine kinase inhibitor indicated for the treatment of.chronic fibrosis with interstitial lung disease from systemic sclerosis showed an annual rate lower than with placebo.
An intracellular inhibitor of tyrosine kinase that inhibits processes involved in the progression of lung fibrosis.
In patients with progressive fibrosing interstitial lung disease, the annual rate of decline in the FVC is significantly lowered among patients who receive nintedanib than those who receive placebo (FlahertyKR).
Approved for adults with scleroderma.
Used in antisynthetase syndrome.
Mainly gastrointestinal adverse events, include diarrhea, followed by nausea, vomiting, and weight loss.
May cause fetal harm, blood clots, bleeding, and gastrointestinal perforation..